Santa Cruz Biotechnology offers a broad range of HIV-2 gp39 monoclonal antibodies for research focused on understanding the complexities of HIV-2 infection. HIV-2 gp39 Antibodies are compatible with multiple experimental applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). HIV-2 gp39 is a critical envelope glycoprotein that plays a significant role in viral entry and immune evasion. Understanding the function of HIV-2 gp39 is essential for developing therapeutic strategies and vaccines against HIV-2, which is less prevalent but still poses a significant public health challenge. The study of HIV-2 gp39 can provide insights into the mechanisms of viral pathogenesis and the host immune response. Research into HIV-2 gp39 continues to reveal new aspects of viral biology and potential therapeutic targets. Investigating the structure and function of HIV-2 gp39 helps scientists better understand viral transmission and infection mechanisms. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific knowledge and contribute to the development of new treatments for HIV-2 infection.